Catheter ablation as the first-line therapy for atrial fibrillation: update on evidence and clinical implications

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2025.0001

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Therapy for atrial fibrillation has markedly evolved over the past two decades. Advancements in technology and growing therapeutic options have led to reexamination of the current evidence. New guidelines have also been updated and published across continents. This reappraisal of the contemporary data assesses the overall treatment strategies for patients with atrial fibrillation and examines how atrial fibrillation ablation ranks among the hierarchy of therapeutic modalities. The role of catheter ablation as a first-line therapy in selected patients with atrial fibrillation is emphasized, and a selective discussion of catheter ablation in patients with heart failure is included.

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Mingze

Olubadewa A. Fatunde and Win-Kuang Shen. Catheter Ablation as the First-Line Therapy for Atrial Fibrillation: Update on Evidence and Clinical Implications. CVIA. 2025. Vol. 10(1). DOI: 10.15212/CVIA.2025.0001